Drug Profile
Research programme: liver X receptor agonists - Daiichi Sankyo
Alternative Names: R 211945Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 15 Nov 2011 Final pharmacodynamics data from a preclinical trial in Atherosclerosis presented at the 84th Annual Scientific Sessions of the American Heart Association (AHA-2011)
- 12 Nov 2011 Preclinical trials in Atherosclerosis in USA (PO)